20494947

Source:http://linkedlifedata.com/resource/pubmed/id/20494947

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023911, umls-concept:C0861876, umls-concept:C1516119
pubmed:issue	8
pubmed:dateCreated	2010-7-27
pubmed:abstractText	Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials. The efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation, however, has not been determined.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0313225
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/sorafenib
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1465-3621
pubmed:author	pubmed-author:AhnChul-SooCS, pubmed-author:HwangShinS, pubmed-author:KangYoon-KooYK, pubmed-author:KimKi-HunKH, pubmed-author:KimTae WonTW, pubmed-author:LeeHan ChuHC, pubmed-author:LeeSung-GyuSG, pubmed-author:MoonDeok-BogDB, pubmed-author:RyooBaek-YeolBY, pubmed-author:RyuMin-HeeMH, pubmed-author:SuhDong JinDJ, pubmed-author:YoonDok HyunDH
pubmed:issnType	Electronic
pubmed:volume	40
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	768-73
pubmed:dateRevised	2010-10-4
pubmed:meshHeading	pubmed-meshheading:20494947-Adult, pubmed-meshheading:20494947-Antineoplastic Agents, pubmed-meshheading:20494947-Benzenesulfonates, pubmed-meshheading:20494947-Carcinoma, Hepatocellular, pubmed-meshheading:20494947-Disease Progression, pubmed-meshheading:20494947-Drug Eruptions, pubmed-meshheading:20494947-Female, pubmed-meshheading:20494947-Hematologic Diseases, pubmed-meshheading:20494947-Humans, pubmed-meshheading:20494947-Liver Neoplasms, pubmed-meshheading:20494947-Liver Transplantation, pubmed-meshheading:20494947-Male, pubmed-meshheading:20494947-Middle Aged, pubmed-meshheading:20494947-Neoplasm Recurrence, Local, pubmed-meshheading:20494947-Protein Kinase Inhibitors, pubmed-meshheading:20494947-Pyridines, pubmed-meshheading:20494947-Retrospective Studies, pubmed-meshheading:20494947-Survival Rate
pubmed:year	2010
pubmed:articleTitle	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
pubmed:affiliation	Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea.
pubmed:publicationType	Journal Article